diseases include but are not limited to the group consisting of pulmonary oxygen toxicity, adult respiratory distress syndrome, bronchopulmonary dysplasia, Chronic Obstructive Lung Disease, pulmonary fibrosis, sepsis syndrome, Parkinson's disease, Alzheimer's, autism and other neurodegenerative diseases including conditions of inflammatory dementia, encephalitis, endotoxemia, anoxia induced neuronal damage, ischemic reperfusion injury, inflammatory diseases, systemic lupus erythematosis, myocardial infarction, stroke, traumatic hemorrhage, spinal cord trauma, Crohn's disease, rheumatoid arthritis, diabetes, cataract formation, uvetis, macular degeneration, emphysema, gastric ulcers, oxygen toxicity, neoplasia, undesired cell a compositions of the invention can be used to treat an animal suffering from one or more of the following illnesses from the group consisting of chronic viral infections: HIV, hepatitis C, chronic fatigue, immuno deficiency syndrome, immune deficiencies, cancer, B-cell malignancies, including lymphomas, chronic leukemia, myeloma Waldenstrom's and MGUS to improve immune defense productions and thereby mitigate the progression of the illnesses to thereby limit fatigue
Gerber, P
Milk Thistle Extract (Silybum marianum) (Fruit/Seed) (Standardized to 80 mg Silymarin Flavonoids equivalent 80%), 100 mg
Philpott, Genetics and Metabolism Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9B-16, 10 Center Drive, Bethesda, MD 20892-1800, USA e-mail: [email protected] This article was submitted to Drug Metabolism and Transport, a section of the journal Frontiers in Pharmacology
